Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annovis Bio, Inc. Common Stock (NY:ANVS)

1.620 -0.680 (-29.57%)
Official Closing Price Updated: 7:00 PM EDT, Apr 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Annovis Bio, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
These stocks are moving in today's session ↗
Via Chartmill
Which stocks are experiencing notable movement on Thursday? ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Development in The Scientist Publication
Via Investor Brand Network
News headline image
Annovis Publishes Historical Review of Buntanetap in The Scientist
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Partners With NeuroRPM To Integrate AI Platform In Parkinson Study
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
From NeuroRPM Inc.
Via GlobeNewswire
News headline image
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Receives Positive DSMB Recommendation to Continue Phase 3 Alzheimer’s Trial
Via Investor Brand Network
News headline image
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Launch Open-Label Extension Study of Buntanetap in Parkinson Disease
Via Investor Brand Network
News headline image
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Schedules Corporate Update Webinar and Live Q&A Session
Via Investor Brand Network
News headline image
Annovis to Host Corporate Update Webinar on January 28, 2026
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present New Buntanetap Findings at Parkinson Study Group Annual Meeting
Via Investor Brand Network
News headline image
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Announces Two Presentations at the CTAD 2025 Conference
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
On Thursday, there are stocks with unusual volume. Let's take a look. 
Via Chartmill
News headline image
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia ↗
The meeting with the FDA is scheduled for January 2026. 
Via Stocktwits
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Secures FDA Type C Meeting to Advance Parkinson’s Disease Dementia Program
Via Investor Brand Network
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Annovis Bio Stock Jumps As New Data Shows Buntanetap Halts Cognitive Decline In Parkinson's Patients ↗
Annovis Bio rises after Phase 3 data show buntanetap halted decline in Parkinson's patients, with results in those with amyloid co-pathology. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.